R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study.
Hart R, Burns D, Ramaekers B, Ren S, Gladwell D, Sullivan W, Davison N, Saunders O, Sly I, Cain T, Lee D.
Hart R, et al. Among authors: sullivan w.
Pharmacoeconomics. 2020 Jul;38(7):765-776. doi: 10.1007/s40273-020-00903-9.
Pharmacoeconomics. 2020.
PMID: 32236891
Free article.